Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Status:
RECRUITING
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Gustavo A Heresi, MD, MS
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) The Cleveland Clinic